Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAV-PD: Methylphenidate for Apathy in Parkinson's Disease
NCT05669170Phase 2Not yet recruiting
- Sponsor
- Ralph H. Johnson VA Medical Center
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of methylphenidate in apathy, sponsored by Ralph H. Johnson VA Medical Center. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
methylphenidate
03
Conditions
apathy
Beyond the preview
Go deeper on NCT05669170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669170.